Cardiff Oncology Reports High Tumor Response in Mid-Stage Onvansertib Trial; Shares Rise Pre-Bell

MT Newswires Live12-10

Cardiff Oncology (CRDF) said Tuesday that preliminary results from a mid-stage study of its cancer treatment candidate onvansertib showed an overall 57% objective response rate, or ORR, in patients with a specific metastatic colorectal cancer.

Patients who received a 30 milligram dose of onvansertib in addition to standard of care had a 64% ORR, while those who received 20 milligram plus standard of care had a 50% ORR, Cardiff said.

Cardiff reported a "deeper tumor response" in those who received a 30 milligram dose compared with those who received 20 milligram.

The safety profiles of both doses are similar, with no major or unexpected toxicities observed, the company added.

The company said it plans to report additional data from the ongoing study in the first half of next year.

Shares of the company were up nearly 40% in recent Tuesday premarket activity.

Price: 3.40, Change: +0.96, Percent Change: +39.34

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2490091959?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-10 19:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2490091959","market":"nz","top_or_hot":-1,"title":"Cardiff Oncology Reports High Tumor Response in Mid-Stage Onvansertib Trial; Shares Rise Pre-Bell","media":"MT Newswires Live","content":"<html><body><p> Cardiff Oncology (CRDF) said Tuesday that preliminary results from a mid-stage study of its cancer treatment candidate onvansertib showed an overall 57% objective response rate, or ORR, in patients with a specific metastatic colorectal cancer.</p><p>Patients who received a 30 milligram dose of onvansertib in addition to standard of care had a 64% ORR, while those who received 20 milligram plus standard of care had a 50% ORR, Cardiff said.</p><p>Cardiff reported a \"deeper tumor response\" in those who received a 30 milligram dose compared with those who received 20 milligram.</p><p>The safety profiles of both doses are similar, with no major or unexpected toxicities observed, the company added.</p><p>The company said it plans to report additional data from the ongoing study in the first half of next year.</p><p>Shares of the company were up nearly 40% in recent Tuesday premarket activity.</p><p>Price: 3.40, Change: +0.96, Percent Change: +39.34</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cardiff Oncology Reports High Tumor Response in Mid-Stage Onvansertib Trial; Shares Rise Pre-Bell</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCardiff Oncology Reports High Tumor Response in Mid-Stage Onvansertib Trial; Shares Rise Pre-Bell\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-10 19:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cardiff Oncology (CRDF) said Tuesday that preliminary results from a mid-stage study of its cancer treatment candidate onvansertib showed an overall 57% objective response rate, or ORR, in patients ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2490091959","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490091959","pubTimestamp":1733831564,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Cardiff Oncology  said Tuesday that preliminary results from a mid-stage study of its cancer treatment candidate onvansertib showed an overall 57% objective response rate, or ORR, in patients with a specific metastatic colorectal cancer.Patients who received a 30 milligram dose of onvansertib in addition to standard of care had a 64% ORR, while those who received 20 milligram plus standard of care had a 50% ORR, Cardiff said.Cardiff reported a \"deeper tumor response\" in those who received a 30 milligram dose compared with those who received 20 milligram.The safety profiles of both doses are similar, with no major or unexpected toxicities observed, the company added.The company said it plans to report additional data from the ongoing study in the first half of next year.Shares of the company were up nearly 40% in recent Tuesday premarket activity.Price: 3.40, Change: +0.96, Percent Change: +39.34","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CRDF":"Cardiff Oncology, Inc.","SSI":"Stage Stores Inc"},"translate_title":"Cardiff Oncology报告中期Onvansertib试验中肿瘤反应高；盘前股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SSI":1,"CRDF":0.9},"content_text":"Cardiff Oncology (CRDF) said Tuesday that preliminary results from a mid-stage study of its cancer treatment candidate onvansertib showed an overall 57% objective response rate, or ORR, in patients with a specific metastatic colorectal cancer.Patients who received a 30 milligram dose of onvansertib in addition to standard of care had a 64% ORR, while those who received 20 milligram plus standard of care had a 50% ORR, Cardiff said.Cardiff reported a \"deeper tumor response\" in those who received a 30 milligram dose compared with those who received 20 milligram.The safety profiles of both doses are similar, with no major or unexpected toxicities observed, the company added.The company said it plans to report additional data from the ongoing study in the first half of next year.Shares of the company were up nearly 40% in recent Tuesday premarket activity.Price: 3.40, Change: +0.96, Percent Change: +39.34","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490091959"}